Biomarkers such as PD-L1 expression [7,8], tumor mutation burden (TMB) [9], neoantigen load [10], tumor infiltrating immune and stromal cells [11], and immune-regulatory mRNA expression [12] may be suitable for clinical selection of patients receiving ICBs, but the utility of each marker is limited. This evidence concerns the gene CD274 and neoplasm.